Answers are grounded in this paper and cite their sources.
Background It is unclear whether documented cannabis use disclosure is independently associated with opioid prescribing practices when patients discharge from the Emergency Department (ED). Objective To examine associations between cannabis use disclosure and opioid prescribing aas well as dose among adults with selected acute painful conditions. Methods We conducted a retrospective observational study of adult patients seen in the ED between 2021-2023 in a Southern California healthcare system. For patients with multiple ED visits, only the earliest encounter was included in the study. Eligible conditions included major/long-bone fractures, acute low-back/lumbar/sciatic conditions, and selected minor acute musculoskeletal injuries. The primary outcome was an opioid prescription at discharge. Among who were prescribed an opioid, secondary outcomes were total and daily prescribed morphine milligram equivalents (MME). Multivariable models adjusted for demographic, clinical, substance-use, utilization, year, and diagnosis variables. Results Among 3,159 patients, 507 (16.0%) disclosed cannabis use. Opioids were prescribed to 27.6% of cannabis-disclosing and 31.3% of documented non-cannabis patients (absolute difference, −3.6 percentage points; 95% CI, −7.9 to 0.6). Cannabis disclosure was not associated with discharge opioid prescribing after adjusting for covariates (adjusted odds ratio, 0.86; 95% CI, 0.67–1.11). Among opioid recipients, cannabis disclosure was not associated with total MME (adjusted mean ratio, 1.11; 95% CI, 0.92–1.34) or daily MME (1.07; 95% CI, 0.95–1.21). Conclusions Documented cannabis disclosure was not independently associated with opioid prescribing at ED discharge or prescribed opioid dose.
No takes yet. Share an insight, caveat, or question.
Clobes et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: